INTEGRATED BIOPHARMA INC Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q3 2010 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Integrated Biopharma Inc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q3 2010 to Q1 2024.
  • Integrated Biopharma Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2024 was $352K, a 665% increase year-over-year.
  • Integrated Biopharma Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending March 31, 2024 was -$63K, a 115% decline year-over-year.
  • Integrated Biopharma Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $100K, a 96.1% decline from 2022.
  • Integrated Biopharma Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $2.6M, a 64.2% decline from 2021.
  • Integrated Biopharma Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was $7.25M.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$63K $352K +$306K +665% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 -$369K -$452K -$407K -904% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-12
Q3 2023 $38K -$46K -$62K -388% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $100K $83K -$324K -79.6% Apr 1, 2023 Jun 30, 2023 10-K 2023-09-15
Q1 2023 $424K $46K -$914K -95.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 $1.34M -$45K -$736K -107% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-12
Q3 2022 $2.07M $16K -$523K -97% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $2.6M $407K -$2.54M -86.2% Apr 1, 2022 Jun 30, 2022 10-K 2023-09-15
Q1 2022 $5.13M $960K -$746K -43.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $5.88M $691K -$438K -38.8% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-10
Q3 2021 $6.32M $539K -$929K -63.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $7.25M $2.94M Apr 1, 2021 Jun 30, 2021 10-K 2022-09-13
Q1 2021 $1.71M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $1.13M Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-10
Q3 2020 $1.47M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q3 2014 $311K $432K +$91K +26.7% Jul 1, 2014 Sep 30, 2014 10-Q 2014-11-07
Q2 2014 $220K -$156K -$935K -120% Apr 1, 2014 Jun 30, 2014 10-K 2014-09-08
Q1 2014 $1.16M -$423K +$104K +19.7% Jan 1, 2014 Mar 31, 2014 10-Q 2014-05-14
Q4 2013 $1.05M $458K -$370K -44.7% Oct 1, 2013 Dec 31, 2013 10-Q/A 2014-02-13
Q3 2013 $1.42M $341K +$1.31M Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-07
Q2 2013 $110K $779K +$2.37M Apr 1, 2013 Jun 30, 2013 10-K 2014-09-08
Q1 2013 -$2.26M -$527K +$192K +26.7% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-14
Q4 2012 -$2.45M $828K +$1.59M Oct 1, 2012 Dec 31, 2012 10-Q/A 2014-02-13
Q3 2012 -$4.04M -$970K -$1.33M -367% Jul 1, 2012 Sep 30, 2012 10-Q 2012-11-19
Q2 2012 -$2.7M -$1.59M -$1.24M -352% Apr 1, 2012 Jun 30, 2012 10-K 2013-09-30
Q1 2012 -$1.47M -$719K +$151K +17.4% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-15
Q4 2011 -$1.62M -$759K -$124K -19.5% Oct 1, 2011 Dec 31, 2011 10-Q 2013-02-19
Q3 2011 -$1.49M $363K +$763K Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-19
Q2 2011 -$2.26M -$351K Apr 1, 2011 Jun 30, 2011 10-K 2012-10-15
Q1 2011 -$870K Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-21
Q4 2010 -$635K Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-21
Q3 2010 -$400K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.